• Study of obinutuzumab to reduce PLA2R antibodies in patients with primary membranous nephropathy

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Comparing amoxicillin-clavulanate alone versus amoxicillin-clavulanate with ciprofloxacin for treating chemotherapy-induced fever in adult hematology patients

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

    Not yet recruiting

    2 1 1
    Spain
  • Evaluating shorter duration of pembrolizumab and pemetrexed treatment in patients with metastatic non-small cell lung cancer who have not progressed after 6 months

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study of semaglutide effects on inflammation markers in patients with type 2 diabetes mellitus who have high cardiovascular risk

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study of CMP-CPS-001 injection in healthy volunteers and patients with abnormal ornithine transcarbamylase (OTC) genotype for treating urea cycle disorders

    Not yet recruiting

    1 1
    Investigated diseases:
    The Netherlands
  • Study of Lepidoglyphus destructor allergen extract using skin prick tests in patients with allergies

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Spain
  • Study of amivantamab and pemetrexed for patients with non-small cell lung cancer who have EGFR exon20 insertion mutations and cannot receive platinum therapy

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

powered by